Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension

Journal of Clinical Hypertension

Volumn 15, Issue 3, 2013, Pages 186-192

  Karns, Adam ^a   Bral, Jacqueline M ^a   Hartman, Daniel ^b   Peppard, Thomas ^b   Schumacher, Christoph ^c  

^a Medical Corporation   (United States)

^b The Great Lakes Drug Development Inc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

18 HYDROXYDEOXYCORTICOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ALDOSTERONE SYNTHASE; EPLERENONE; LCI 699; PLACEBO; RENIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ALDOSTERONE RELEASE; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG TOLERANCE; FEMALE; HORMONE SYNTHESIS; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SIDE EFFECT; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; ALDOSTERONE SYNTHASE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; ICELAND; IMIDAZOLES; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; PYRIDINES; SPIRONOLACTONE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84874556469     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12051     Document Type: Article

References (26)

1. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005;14:235-241.
2. Cohn JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006;97:4F-12F.
3. Pimenta E, Calhoun DA. Aldosterone, dietary salt, and renal disease. Hypertension 2006;48:209-210.
4. Funder JW, Mihailidou AS. Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol 2009;301:2-6.
5. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004;351:33-41.
6. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis 2010;52:401-409.
7. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-1419.
8. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-1058.
9. Funder JW. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 2007;7:151-157.
10. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
11. Pitt B, Remme W, Zannad F, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
12. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
13. Václavík J, Sedlák R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011;57:1069-1075.
14. Williams GH, Burgess E, Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004;93:990-996.
15. Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, et al. Aldosterone excess or escape: treating resistant hypertension. J Clin Hypertens 2009;11:245-252.
16. Brown R, Quirk J, Kirkpatrick P. Eplerenone. Nat Rev Drug Discov 2003;2:177-178.
17. Schriffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006;47:312-318.
18. Menard J, Watson C, Rebello S, et al. Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects. J Am Coll Cardiol 2010;55:A61.E581.
19. Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010;56:831-838.
20. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011;124:1945-1955.
21. Chapman N, Dobson J, Wilson S, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845.
22. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008;2:462-468.
23. Andersen K, Hartman D, Peppard T, et al. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens 2012;14:580-587.
24. Stas S, Whaley-Connell AT, Sowers JR. Aldosterone and hypertension in the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008;10:94-96.
25. Yu Y, Wei SG, Zhang ZH, et al. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?Hypertension 2008;51:727-733.
26. Hollenberg NK. Aldosterone synthase inhibition: a promising beginning. Curr Hypertens Rep 2011;13:99-102.